Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
DXCM · Nasdaq · Healthcare
Fundamental quality
92
out of 100
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its profitability drags it down the most.
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2021 | $2,449M | $217M | $53M | -$1,053M |
| 2022 | $2,910M | $341M | $305M | -$642M |
| 2023 | $3,622M | $542M | $512M | -$566M |
| 2024 | $4,033M | $576M | $631M | -$606M |
| 2025 | $4,662M | $836M | $1,077M | -$918M |
Between 2021 and 2025, revenue went from $2,449M to $4,662M (+90%) and net income went from $217M to $836M (+286%).
Annual figures in U.S. dollars per SEC filings. Net debt is total debt minus cash.
Is Dexcom Inc a profitable company?
Yes. Dexcom Inc shows a net margin of 19.3% and an ROE of 31.5%, a sign of a profitable business.
Does Dexcom Inc have a lot of debt?
No. Dexcom Inc has a net cash position: more cash than debt.
Is Dexcom Inc growing?
Its revenue has grown 16.8% annualized in recent years and its earnings per share 37.9%.
Does Dexcom Inc generate cash?
Yes. It converts about 29.7% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is Dexcom Inc cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →